Puerarin regulates neovascular glaucoma through pigment epithelium‑derived growth factor‑induced NF‑κB signaling pathway

Wei,Hui‑Yu; Zhang,Ya‑Jie; Zhao,Shao‑Zhen

doi:10.3892/mmr.2018.8800

Puerarin regulates neovascular glaucoma through pigment epithelium‑derived growth factor‑induced NF‑κB signaling pathway

Authors:
- Hui‑Yu Wei
- Ya‑Jie Zhang
- Shao‑Zhen Zhao
View Affiliations

Affiliations: Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute, Tianjin Medical University College of Optometry, Tianjin 300384, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/mmr.2018.8800
Pages: 7866-7874

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neovascular glaucoma is an ophthalmic disease and a potentially blinding secondary glaucoma caused by the formation of abnormal new blood vessels on the iris, which can prevent the normal drainage of water from the anterior segment of the eye. Evidence from China has suggested that puerarin benefits many diseases including myocardial infarction, stable angina, cerebral ischemia and glaucoma in a clinical setting. In the present study, the aim was to investigate the efficacies of puerarin on neovascular glaucoma in a mouse model. The molecular mechanism of puerarin‑mediated treatment for neovascular glaucoma was also investigated both in vitro and in vivo. Inflammatory responses in mice with neovascular glaucoma were analyzed by western blotting. Oxidative stress levels were investigated following treatment with puerarin in a mouse model of neovascular glaucoma. The results indicated that puerarin markedly improved growth of vascular endothelial cells. The present study reported that puerarin treatment markedly decreased interleukin (IL)‑1β, IL‑17A and tumor necrosis factor‑α expression levels in mice with neovascular glaucoma. It was found that puerarin significantly decreased oxidative stress levels by reducing reactive oxygen species, superoxide dismutase and malondialdehyde levels, as well as neuronal nitric oxide synthase (NOS) and inducible NOS expression levels. Results indicated that expression levels of pigment epithelium‑derived growth factor were significantly inhibited following treatment with puerarin. Mechanism analysis demonstrated that treatment with puerarin effectively inhibited nuclear factor (NF)‑κB activity and its target protein levels p65, inhibitor of NF‑κB kinase subunit β and inhibitor of NF‑κB kinase subunit α in vascular endothelial cells. Increasing endothelial‑derived growth factor (EDGF) expression levels could stimulate NF‑κB activity and abolish the inhibitory effects of puerarin. An animal study reported that puerarin treatment presented therapeutic effects for mice with neovascular glaucoma. Numbers of new vessels in iris were recovered to normal following puerarin treatment. In conclusion, these results indicated that puerarin treatment can inhibit inflammatory responses and oxidative stress, platelet‑derived growth factor (PDGF) expression and NF‑κB activity, suggesting puerarin may be a potential agent for the treatment of neovascular glaucoma through PDGF‑induced NF‑κB signaling pathway.

View Figures

View References

1	Ng E, Choong AM and Walker PJ: Neovascular glaucoma post carotid endarterectomy: A case report and review of the literature. Ann Vasc Dis. 8:103–105. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kiddee W, Tantisarasart T and Wangsupadilok B: Neovascular glaucoma: A retrospective review of 5-year experience in Songklanagarind Hospital. J Med Assoc Thai. 95 Suppl 4:S36–S42. 2012.PubMed/NCBI
3	Martinez-Carpio PA, Bonafonte-Márquez E, Heredia-Garcia CD and Bonafonte-Royo S: Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: Systematic review. Arch Soc Esp Oftalmol. 83:579–588. 2008.(In Spanish). View Article : Google Scholar : PubMed/NCBI
4	Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M and Tanihara H: Trabeculectomy with mitomycin C for neovascular glaucoma: Prognostic factors for surgical failure. Am J Ophthalmol. 147(912–918): e12009.
5	Mishra KK, Daftari IK, Weinberg V, Cole T, Quivey JM, Castro JR, Phillips TL and Char DH: Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: A detailed analysis of tumor and dose-volume parameters. Int J Radiat Oncol Biol Phys. 87:330–336. 2013. View Article : Google Scholar : PubMed/NCBI
6	Goto A, Inatani M, Inoue T, Awai-Kasaoka N, Takihara Y, Ito Y, Fukushima M and Tanihara H: Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. J Glaucoma. 22:572–576. 2013. View Article : Google Scholar : PubMed/NCBI
7	Calugaru D and Calugaru M: Neovascular glaucoma-etipathogeny and diagnosis. Oftalmologia. 56:3–14. 2012.(In Romanian). PubMed/NCBI
8	Rachitskaya AV, Lee RK, Dubovy SR and Schiff ER: Combined central retinal vein and central retinal artery occlusions and neovascular glaucoma associated with interferon treatment. Eur J Ophthalmol. 22:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
9	Altintas AG, Arifoglu HB, Tutar E, Koklu G and Ozcan PY: Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol. 31:124–127. 2012. View Article : Google Scholar : PubMed/NCBI
10	Caujolle JP, Maschi C, Freton A, Pages G and Gastaud P: Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: Preliminary results. Ophthalmic Res. 47:57–60. 2012. View Article : Google Scholar : PubMed/NCBI
11	Călugăru D and Călugăru M: Treatment of neovascular glaucoma. Oftalmologia. 56:20–39. 2012.(In Romanian).
12	Zhou WY and Li YH: A survey on treatment of dry eye by traditional chinese medicine and integrative chinese and Western medicine. Chin J Integr Med. 12:154–159. 2006. View Article : Google Scholar : PubMed/NCBI
13	Mi XS, Zhong JX, Chang RC and So KF: Research advances on the usage of traditional Chinese medicine for neuroprotection in glaucoma. J Integr Med. 11:233–240. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhang HY, Yi XN, Liu YH, Lao ML and Zhang XF: The protective effect of puerarin on Abeta(25–35)-induced PC12 cell injury. Zhong Yao Cai. 33:763–767. 2010.(In Chinese). PubMed/NCBI
15	Zhang W, Liu CQ, Wang PW, Sun SY, Su WJ, Zhang HJ, Li XJ and Yang SY: Puerarin improves insulin resistance and modulates adipokine expression in rats fed a high-fat diet. Eur J Pharmacol. 649:398–402. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang L and Zhao Y: Effect of decoction method on pharmacokinetics of puerarin in dogs. Zhong Yao Cai. 33:1442–1444. 2010.(In Chinese). PubMed/NCBI
17	Li J, Wang G, Liu J, Zhou L, Dong M, Wang R, Li X, Li X, Lin C and Niu Y: Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo. Eur J Pharmacol. 649:195–201. 2010. View Article : Google Scholar : PubMed/NCBI
18	Liu CM, Ma JQ and Sun YZ: Puerarin protects the rat liver against oxidative stress-mediated DNA damage and apoptosis induced by lead. Exp Toxicol Pathol. 64:575–582. 2012. View Article : Google Scholar : PubMed/NCBI
19	Feng ZQ, Wang YY, Guo ZR, Chu FM and Sun PY: The synthesis of puerarin derivatives and their protective effect on the myocardial ischemia and reperfusion injury. J Asian Nat Prod Res. 12:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
20	Xiao S, Wang J and Xiao N: MicroRNAs as noninvasive biomarkers in bladder cancer detection: A diagnostic meta-analysis based on qRT-PCR data. Int J Biol Markers. 31:e276–e285. 2016. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-based quantitative assay for screening of kidney stone disease. Biol Proced Online. 11:145–160. 2009. View Article : Google Scholar : PubMed/NCBI
23	Steinhart MR, Cone FE, Nguyen C, Nguyen TD, Pease ME, Puk O, Graw J, Oglesby EN and Quigley HA: Mice with an induced mutation in collagen 8A2 develop larger eyes and are resistant to retinal ganglion cell damage in an experimental glaucoma model. Mol Vis. 18:1093–1106. 2012.PubMed/NCBI
24	Tanaka T, Imamura T, Yoneda M, Irie A, Ogi H, Nagata M, Yoshida R, Fukuma D, Kawahara K, Shinohara M and Nakayama H: Enhancement of active MMP release and invasive activity of lymph node metastatic tongue cancer cells by elevated signaling via the TNF-α-TNFR1-NF-kB pathway and a possible involvement of angiopoietin-like 4 in lung metastasis. Int J Oncol. 49:1377–1384. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ao X, Sellati TJ and Stenken JA: Enhanced microdialysis relative recovery of inflammatory cytokines using antibody-coated microspheres analyzed by flow cytometry. Anal Chem. 76:3777–3784. 2004. View Article : Google Scholar : PubMed/NCBI
26	Awodele O, Oreagba IA, Olayemi SO, Oladipo I, Iruegbukpe CO, Balogun BG, Balogun MM and Adedokun AO: Evaluation and comparison of the indices of systemic oxidative stress among Black-africans with Age-related cataracts or primary glaucoma. Middle East Afr J Ophthalmol. 22:489–494. 2015. View Article : Google Scholar : PubMed/NCBI
27	Jeon S, Lee NY and Park CK: Neovascular glaucoma following stereotactic radiosurgery for an optic nerve glioma: A case report. Korean J Ophthalmol. 24:252–255. 2010. View Article : Google Scholar : PubMed/NCBI
28	Widder RA, Lemmen KD and Dietlein TS: Neovascular glaucoma. Klin Monbl Augenheilkd. 227:R15–R27. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
29	Toyama S, Tsuji H, Mizoguchi N, Nomiya T, Kamada T, Tokumaru S, Mizota A, Ohnishi Y and Tsujii H: Working Group for Ophthalmologic Tumors: Long-term results of carbon ion radiation therapy for locally advanced or unfavorably located choroidal melanoma: Usefulness of CT-based 2-port orthogonal therapy for reducing the incidence of neovascular glaucoma. Int J Radiat Oncol Biol Phys. 86:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wittström E, Holmberg H, Hvarfner C and Andréasson S: Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. Eur J Ophthalmol. 22:563–574. 2012. View Article : Google Scholar : PubMed/NCBI
31	Laplace O: Surgical session: Neovascular glaucoma and anti-vascular endothelial growth factor treatment. J Fr Ophtalmol. 32:230–235. 2009.(In French). View Article : Google Scholar : PubMed/NCBI
32	Simha A, Braganza A, Abraham L, Samuel P and Lindsley K: Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev: CD007920. 2013. View Article : Google Scholar
33	Reilly CM, Morris R and Dubielzig RR: Canine goniodysgenesis-related glaucoma: A morphologic review of 100 cases looking at inflammation and pigment dispersion. Vet Ophthalmol. 8:253–258. 2005. View Article : Google Scholar : PubMed/NCBI
34	Chang L, Wong T, Ohbayashi M, Bunce C, Barton K, Ono SJ and Khaw PT: Increased mast cell numbers in the conjunctiva of glaucoma patients: A possible indicator of preoperative glaucoma surgery inflammation. Eye (Lond). 23:1859–1865. 2009. View Article : Google Scholar : PubMed/NCBI
35	Furtado JM, Paula JS, Soares EG, Dhegaide NH, Rocha EM, Donadi E and Mde Rodrigues L: Conjunctival inflammation in patients under topical glaucoma treatment with indication to surgery. Acta Cir Bras. 27:732–735. 2012. View Article : Google Scholar : PubMed/NCBI
36	Vohra R, Tsai JC and Kolko M: The role of inflammation in the pathogenesis of glaucoma. Surv Ophthalmol. 58:311–320. 2013. View Article : Google Scholar : PubMed/NCBI
37	Ha Y, Liu H, Xu Z, Yokota H, Narayanan SP, Lemtalsi T, Smith SB, Caldwell RW, Caldwell RB and Zhang W: Endoplasmic reticulum stress-regulated CXCR3 pathway mediates inflammation and neuronal injury in acute glaucoma. Cell Death Dis. 6:e19002015. View Article : Google Scholar : PubMed/NCBI
38	Schlötzer-Schrehardt U: Oxidative stress and pseudoexfoliation glaucoma. Klin Monbl Augenheilkd. 227:108–113. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
39	Mangan BG, Al-Yahya K, Chen CT, Gionfriddo JR, Powell CC, Dubielzig RR, Ehrhart EJ and Madl JE: Retinal pigment epithelial damage, breakdown of the blood-retinal barrier, and retinal inflammation in dogs with primary glaucoma. Vet Ophthalmol. 10 Suppl 1:S117–S124. 2007. View Article : Google Scholar
40	Tezel G, Yang X, Luo C, Kain AD, Powell DW, Kuehn MH and Kaplan HJ: Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci. 51:5071–5082. 2010. View Article : Google Scholar : PubMed/NCBI
41	Chi W, Chen H, Li F, Zhu Y, Yin W and Zhuo Y: HMGB1 promotes the activation of NLRP3 and caspase-8 inflammasomes via NF-kB pathway in acute glaucoma. J Neuroinflammation. 12:1372015. View Article : Google Scholar : PubMed/NCBI
42	Itakura T, Peters DM and Fini ME: Glaucomatous MYOC mutations activate the IL-1/NF-kB inflammatory stress response and the glaucoma marker SELE in trabecular meshwork cells. Mol Vis. 21:1071–1084. 2015.PubMed/NCBI